Compare · ABT vs PGEN
ABT vs PGEN
Side-by-side comparison of Abbott Laboratories (ABT) and Precigen Inc. (PGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PGEN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 77.1x PGEN ($2.61B).
- Over the past year, ABT is down 11.8% and PGEN is up 71.5% - PGEN leads by 83.3 points.
- PGEN has been more active in the news (12 items in the past 4 weeks vs 8 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 4 for PGEN).
- Company
- Abbott Laboratories
- Precigen Inc.
- Price
- $116.11-0.50%
- $7.28+1.61%
- Market cap
- $200.95B
- $2.61B
- 1M return
- +11.04%
- +34.32%
- 1Y return
- -11.76%
- +71.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 4
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Precigen Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest PGEN
- Director Agee Nancy H bought $24,662 worth of shares (3,411 units at $7.23), increasing direct ownership by 1% to 309,187 units (SEC Form 4)
- Chief Legal Officer Lehr Donald P. converted options into 5,208 shares and covered exercise/tax liability with 2,488 shares, increasing direct ownership by 0.36% to 758,181 units (SEC Form 4) (tax liability)
- Chief Financial Officer Thomasian Harry Jr. converted options into 7,291 shares and covered exercise/tax liability with 3,577 shares, increasing direct ownership by 1% to 258,249 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Shah Rutul R exercised 57,500 shares at a strike of $2.03, sold $375,000 worth of shares (50,000 units at $7.50) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,647 shares, increasing direct ownership by 0.83% to 468,865 units (SEC Form 4) (withholding tax)
- Chief Commercial Officer Tennant Phil exercised 84,374 shares at a strike of $1.51, covered exercise/tax liability with 2,585 shares and sold $593,745 worth of shares (79,166 units at $7.50) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 141,992 units (SEC Form 4) to satisfy withholding tax
- President and CEO Sabzevari Helen converted options into 20,833 shares and covered exercise/tax liability with 10,184 shares, increasing direct ownership by 0.28% to 3,779,521 units (SEC Form 4) to satisfy withholding obligation
- Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
- Chief Operating Officer Shah Rutul R sold $224,590 worth of shares (32,739 units at $6.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 465,012 units (SEC Form 4)
- SEC Form 10-Q filed by Precigen Inc.
- Precigen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits